Trial Profile
Special Drug Use-Results Survey of OPDIVO (all case surveillance) [unresectable or metastatic renal cell cancer]
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Oct 2022
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions
- Sponsors Ono Pharmaceutical
- 18 Oct 2022 Status changed from active, no longer recruiting to completed.
- 01 Oct 2018 Status has been changed to active, no longer recruiting.
- 24 Aug 2018 New trial record